Side Effects of lasmiditan: A Synthesis of Findings from 18 Studies

  1. Home
  2. Side Effects of lasmiditan
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of lasmiditan: A Synthesis of Findings from 18 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of lasmiditan: A Synthesis of Findings from 18 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Lasmiditan is a new migraine medication that selectively targets 5-HT1F receptors, unlike triptans which target 5-HT1B/1D receptors. This selectivity differentiates lasmiditan from triptans by reducing vasoconstriction, making it a potential option for patients with cardiovascular issues. 11 , 15

Studies indicate a higher risk of neuropsychiatric side effects with lasmiditan compared to triptans. 1 Lasmiditan is reported to have a higher risk of mental side effects, neurological side effects, and serotonin syndrome compared to triptans. 1

Conversely, lasmiditan is associated with a lower risk of cardiovascular side effects compared to triptans. 7 , 10 This makes lasmiditan a potentially safer alternative for patients with cardiovascular risks. 14

However, the full range of side effects associated with lasmiditan is not yet fully understood and requires further investigation. 6

Reasons for Side Effects

Lasmiditan's central nervous system action contributes to its higher potential for neuropsychiatric side effects compared to triptans. Furthermore, lasmiditan crosses the blood-brain barrier more easily than triptans, increasing its ability to interact with the brain and potentially cause side effects. 10 , 4

Common Side Effects

Nervous System

The most prevalent side effects of lasmiditan are related to the nervous system. These side effects are generally mild to moderate in severity. Common nervous system side effects include dizziness, tingling sensations, and drowsiness. 11 , 12 , 16 , 18 , 5 , 6 , 4

Psychiatric

Lasmiditan can also trigger psychiatric side effects, typically ranging from mild to moderate. Common psychiatric side effects include elevated mood, autoscopy, and panic attacks. 1

Other

Beyond neuropsychiatric side effects, lasmiditan can cause other side effects, generally mild to moderate. Common side effects include nausea, fatigue, and tiredness. 11 , 10 , 13 , 3

Side Effect Management

Nervous System Side Effects

To manage nervous system side effects, physicians might adjust the dosage or discontinue the medication. 11

Psychiatric Side Effects

If psychiatric side effects develop, consultation with a doctor is advised. They may recommend changing medications or suggesting psychotherapy as needed. 1

Other Side Effects

For other side effects, consulting with a doctor is recommended. They might suggest altering medications or taking steps to alleviate the symptoms as necessary. 11

Comparison Across Studies

Commonalities Across Studies

Studies consistently show that lasmiditan has a weaker vasoconstrictive effect compared to triptans, indicating its potential as a treatment option for individuals with cardiovascular disease. 11 , 15

Differences Across Studies

There is variability in the reported side effects of lasmiditan across studies. For instance, some studies have reported a higher risk of neuropsychiatric side effects with lasmiditan, while others have reported a lower risk. 1

Considerations for Real-World Application

Lasmiditan's reduced vasoconstrictive action compared to triptans makes it a potential option for patients with cardiovascular disease. However, the increased risk of neuropsychiatric side effects with lasmiditan compared to triptans needs to be considered. 1

Lasmiditan offers a potentially valuable treatment option for many individuals with migraine. However, research on the side effects of lasmiditan is still ongoing. Therefore, when using lasmiditan, it's crucial to consult with your doctor and thoroughly understand the risks and benefits associated with the medication. 11

Limitations of Current Research

Research on lasmiditan remains in its early stages, highlighting the need for further investigation. In particular, there's a lack of research on the long-term side effects of lasmiditan and drug interactions. 1 , 16 , 13

Future Research Directions

Research is necessary regarding the long-term side effects of lasmiditan, drug interactions, and its use during pregnancy and breastfeeding. Research is also needed on the appropriate use of lasmiditan and methods to minimize side effects. 10 , 16 , 13 , 6

Conclusion

Lasmiditan's reduced vasoconstrictive effect compared to triptans makes it a potential treatment option for patients with cardiovascular disease. However, lasmiditan is known to have a higher risk of neuropsychiatric side effects than triptans. Therefore, these factors need to be considered when using lasmiditan. Research on lasmiditan is still in its early stages, and further research is needed. 11 , 15 , 1

If you suffer from migraine, it is essential to consult with your doctor and find a treatment plan that is right for you. 11

Literature analysis of 18 papers
Positive Content
18
Neutral Content
0
Negative Content
0
Article Type
2
1
0
13
18
2.

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis.

Author: AhsanMarya, MallickAyaz Khurram

Migraine treatment

This meta-analysis and trial sequential analysis (TSA) assesses the efficacy and tolerability of lasmiditan, a specific 5-HT1F agonist, for treating episodic migraine. Lasmiditan is a new treatment option for migraine.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Lasmiditan for acute treatment of migraine.

Author: ParikhS

Acute migraine treatment
Central side effects

Lasmiditan is a drug that is used to treat migraine headaches. It works by activating a specific type of receptor in the brain that is involved in the transmission of pain signals. This review discusses the development, pharmacology, and safety of lasmiditan.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

The potential of lasmiditan in migraine.

Author: MecklenburgJasper, RaffaelliBianca, NeebLars, Sanchez Del RioMargarita, ReuterUwe

Migraine treatment
Dizziness
Drowsiness
Paresthesia

Lasmiditan, a selective 5-HT<sub>1F</sub> agonist, is a new treatment for acute migraine that lacks triptan-like vasoactive properties. Two phase III trials showed it was more effective than placebo in achieving migraine freedom within 2 hours. While side effects like dizziness, paresthesia, and drowsiness are common, their frequency seems to decrease with repeated use.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan.

Author: KudrowDavid, KregeJohn H, HundemerHans P, BergPaul H, KhannaRashna, OssipovMichael H, Pozo-RosichPatricia

Adverse events
Central nervous system adverse events

The study investigated the differences in reporting of treatment-emergent adverse events (AEs) in phase 2 and phase 3 trials of lasmiditan. Differences in informed consent wording, AE collection methods, translation, and exclusion criteria were identified as potential contributors to the observed differences in AE reporting.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.

Author: ShapiroRobert E, HochstetlerHelen M, DennehyEllen B, KhannaRashna, DotyErin Gautier, BergPaul H, StarlingAmaal J

Safe and effective migraine treatment

Lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist, is being evaluated for its safety and efficacy in acute treatment of migraine attacks in patients with CVRFs.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

8.

The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

Author: van HoogstratenWillem Sebastiaan, MaassenVanDenBrinkAntoinette

Migraine treatment
MOH risk

This study discusses the development of new acutely acting antimigraine drugs, including CGRP receptor antagonists (gepants) and the 5-HT1F receptor agonist lasmiditan. The study explores whether these drugs carry the same risk for developing medication overuse headache (MOH) as older migraine medications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Gepants for the treatment of migraine.

Author: NegroAndrea, MartellettiPaolo

Cardiovascular contraindications
Headache recurrence
Incomplete pain relief

Calcitonin gene-related peptide (CGRP) receptor antagonists, a new class of drugs, show promise for the acute treatment of migraine. They are primarily developed to address the limitations of triptans, the current standard of care, which include incomplete pain relief, high rates of headache recurrence, and side effects. CGRP is a key target for migraine treatments currently under development.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.

Author: NegroAndrea, KoverechAngela, MartellettiPaolo

Minimized side effects
Superior to placebo
Central nervous system effects

Lasmiditan is a new drug for migraine that acts on the 5-HT1<sub>F</sub> receptor, unlike triptans that act on 5-HT1<sub>B</sub>/1<sub>D</sub> receptors. It showed efficacy and a better safety profile in Phase II and III trials compared to placebo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Is selective 5-HT<sub>1F</sub> receptor agonism an entity apart from that of the triptans in antimigraine therapy?

Author: Rubio-BeltránEloísa, Labastida-RamírezAlejandro, VillalónCarlos M, MaassenVanDenBrinkAntoinette

Migraine treatment
Cardiovascular risk

Lasmiditan, a selective 5-HT<sub>1F</sub> receptor agonist, is effective for acute migraine treatment and does not constrict human coronary arteries. This makes it a potential alternative for patients with cardiovascular disease who cannot take triptans.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Side effects associated with current and prospective antimigraine pharmacotherapies.

Author: González-HernándezAbimael, Marichal-CancinoBruno A, MaassenVanDenBrinkAntoinette, VillalónCarlos M

Antimigraine therapy
Cardiovascular side effects

This review discusses the side effects of current and prospective migraine medications. The review highlights the need for new migraine medications with fewer side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Recent advances in the management of migraine.

Author: ObermannMark, HolleDagny

Improved migraine management
Reduced disability
Medication overuse headache
Side effects

Migraine remains a significant health burden. While triptans and other new treatments have emerged, challenges remain, such as side effects and medication overuse headaches. This abstract discusses the evolution of migraine treatment and the need for further research to improve management.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.

Author: RaffaelliBianca, IsraelHeike, NeebLars, ReuterUwe

CNS side effects

Lasmiditan, a selective 5-HT1F receptor agonist, is a novel acute migraine treatment. This article explores the clinical efficacy and safety of lasmiditan, highlighting its potential benefits for patients with cardiovascular risks who cannot take traditional triptan medications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Lasmiditan for the treatment of migraine.

Author: CapiMatilde, de AndrésFernando, LionettoLuana, GentileGiovanna, CipollaFabiola, NegroAndrea, BorroMarina, MartellettiPaolo, CurtoMartina

Lasmiditan efficacy
Migraine treatment
Central nervous system side effects
Limited pharmacokinetic data

Lasmiditan, a novel serotonin1F receptor agonist, is being investigated as a potential acute therapy for migraine. Preclinical and clinical studies have shown promising efficacy without vasoconstrictive effects. However, further research is needed to address concerns about pharmacokinetics, metabolism, and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.

Author: FärkkiläMarkus, DienerHans-Christoph, GéraudGilles, LáinezMiguel, SchoenenJean, HarnerNadja, PilgrimAlison, ReuterUwe,

Migraine treatment

Lasmiditan is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity. This study assessed the efficacy and safety of oral lasmiditan for the acute treatment of migraine.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.